UGCG and cancer: Here, we assessed GCS activities in Genz‐161 treated cancer cells and found that Genz‐161 at 1 μM concentration effectively inhibited GCS activity and Gb3 production in all cells tested; Gb3 levels were extensively suppressed even in WiDr cells that exhibited quite high relative levels of GCS activity (132 fmol/μg).